Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
temozolomide + lomustine
- Development stage
- Unknown
- Lead developer
- Aston University
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Temozolomide + lomustine is a combination chemotherapy regimen consisting of two oral alkylating agents, temozolomide and lomustine. Both drugs work by damaging the DNA of cancer cells, thereby inhibiting their ability to divide and proliferate. This combination has been studied primarily in patients with newly diagnosed glioblastoma with methylated MGMT promoter status, where it is administered alongside radiotherapy. The rationale for combining these agents is based on their complementary mechanisms as DNA-alkylating agents, potentially enhancing antitumor efficacy compared to temozolomide alone. Clinical trials (notably CeTeG/NOA-09 and NRG-BN011) have investigated this regimen for its potential to improve overall survival in this patient population[1][2][3][5].
- Other names
- lomustine-temozolomide combination therapy
02
Targets
DNA
Beyond the preview
Go deeper on temozolomide + lomustine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on temozolomide + lomustine.